Influences of blood lipids on the occurrence and prognosis of hemorrhagic transformation after acute cerebral infarction: a case-control study of 732 patients

Table 6 Major treatment and prognosis for CH and CH post CI [n (%)]

Treatment and prognosis		Group A (n = 628)	Group B (n = 104)	P
rTPA				0.403
	No	550 (87.6)	88 (84.6)
	Yes	78 (12.4)	16 (15.4)
Argatroban				0.363
	No	521 (83.0)	90 (86.5)
	Yes	107 (17.0)	14 (13.5)
LMWH				0.059^*
	No	606 (96.5)	96 (92.3)
	Yes	22 (3.5)	8 (7.7)
Warfarin				0.536^*
	No	624 (99.4)	103 (99.0)
	Yes	4 (0.6)	1 (1.0)
D-Anti-PLT				0.852
	0, no/single	290 (46.2)	47 (45.2)
	1, double	338 (53.8)	57 (54.8)
SILL				0.744
	0, no	443 (70.5)	75 (72.1)
	1, ILL	185 (29.5)	29 (27.9)

rTPAvein thrombolysis with recombinant human tissue plasminogen activator. LMWH: Low-molecular-weight heparin. D-anti-PLT (platelets): Aspirin 100 mg or 300 mg + clopidogrel hydrogen sulfate 75 mg; SILL: Intensive lipid-lowering statins. ^*: Fisher’s exact test (2-sided)

ISSN: 2054-9369